Scancell Share Discussion Threads

[marcusl2] 29/8/2023 07:50

Commenting on his appointment as Chief Financial Officer, Sath Nirmalananthan said:

" I am excited to be joining Scancell at such a pivotal time. With the Phase 2 single arm SCOPE trial progressing and initial topline data readouts expected this year and Modi-1 next year, the Company is positioned with highly valuable science and near-term inflection points that should deliver value to our shareholders. I look forward to working with Lindy and the wider team and am excited by the potential of what can be achieved."

[rogerbridge] 29/8/2023 07:39

The tone is very positive, it looks as though SCLP are expecting positive news ahead with sales and licensing agreements. A very good appointment.

[chillpill] 29/8/2023 07:17

Good to see a streetwise FD appointed.

[marcusl2] 28/8/2023 21:39

Novocure tumbles after electrical fields therapy fails ovarian cancer study

[marcusl2] 28/8/2023 11:24

SC134 – a highly specific antibody targeting small cell lung cancer
SC134 linked with scFv fragment of CD3 mAb –

Avidimab highly valuable

iSC2811 – costimulates TILs resulting in anti-tumour immunity
and enhances T cell engraftment for CAR-T development
Ultraspecific SSEA4 mAb – lead AvidiMab® modified clinical candidate


Jan 2023
GSK is stepping up its interest in T-cell engaging antibodies, handing WuXi Biologics $40 million upfront plus $1.46 billion in additional payments for research, development, regulatory and commercial successes.for an exclusive license to one preclinical bispecific and options on three additional candidates.

WuXi, a service provider, has used its platform technologies to generate antibodies that are designed to bind to CD3 on T cells and tumor-associated antigens (TAAs) expressed by cancers. By hitting multiple targets, the antibodies crosslink cancer cells and T cells and turn the immune system against the tumor.

[trustmeimastomach] 28/8/2023 08:20

We are 34 .. raining at last managed 24c yesterday warmer in the Shires

[marcusl2] 26/8/2023 14:50

Modi-1 treatment were well tolerated in Cohort 4 with no safety concerns. Encouragingly, the first patient to be assessed has shown a tumour regression at their first radiological assessment at 8 weeks. The remaining patients have not yet been assessed radiologically.

[marcusl2] 26/8/2023 14:42

Cossery observed that vaccines are hard and were a backwater- till Covid and BioNTech/ Moderna- but are now a “hot ticket”. He sees the inflection in terms of potential big pharma interest being at the point that there are credible numbers of patients (30-40) in clinical trials (and of course positive readouts).

[marcusl2] 25/8/2023 14:18

Adding Lenvima to Keytruda fails to improve survival in head and neck cancer

Merck & Co. and Eisai announced Friday that the addition of the multiple receptor tyrosine kinase inhibitor Lenvima (Lenvatinib) to Keytruda (pembrolizumab) as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 failed to improve overall survival (OS) compared to the anti-PD-1 therapy alone.

"With the LEAP-010 trial, we aimed to explore whether this combination could improve upon options already available with Keytruda-based regimens for…HNSCC," remarked Gregory Lubiniecki, vice president of global clinical development at Merck Research Laboratories. Keytruda is currently authorised in combination with platinum and fluorouracil for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC.

[rogerbridge] 24/8/2023 15:52

Thank you Marcus. All to play for.

[the real lozan] 24/8/2023 15:43

trustme -
Are you located in France ???
We are in 82... quite lush / green here for August...where are you
Good to see a mon as talks reight

[trustmeimastomach] 24/8/2023 15:06

France plenty in the midlands and up north but nowt down south

[marcusl2] 24/8/2023 14:37

Or maybe a deal for the Immunobody platform?

DNA could be better than mRNA

[marcusl2] 24/8/2023 14:36

chester18

RE: July updateToday 13:55
Hi Burble

Following that train of thought I would suggest that Scib1 is working well in the the patients that currently fit the correct profile. As we know this is a sub-set of melanoma patients.

The move to iSCIB+ triples the number of potential patients which means with the right data results it will be commercially extremely valuable.

The 'would' in that RNS says that a suitor has very possibly laid their cards in the table given iSCIB+ brings in the right level of positive data.

The sooner we are informed that we have approval to move the SCOPE trial to the newer version the better.

Chester.

[marcusl2] 24/8/2023 14:36

Burble

July updateToday 12:52
I was just reading through the July update and something I had missed previously, jumped out at me with regard to the SCIB1+ trial.

'An adapted registration trial could yield Phase 2 data within 2 years and would provide the Company with a pathway to a potential deal. '

The use of the word 'could' [yield Phase 2 data within 2 years] followed by 'would' [provide the company with a pathway to a potential deal]. Does that mean that there is a draft deal on the cards already, subject to results from the iSCIB1+ trial? I wonder who that would be with? Roche? BMS? Someone else?

Surely if this wasn't the case this line would read 'An adapted registration trial could yield Phase 2 data within 2 years and could provide the Company with a pathway to a potential deal.'

Or am I over thinking things?

[the real lozan] 24/8/2023 10:20

trustme 5531 -
"Need some rain down south "
South of where ??? UK,France, Europe, or elsewhere ???

[trustmeimastomach] 24/8/2023 10:04

Need some rain down south Bit warmer this week but I'd say that's it for this year

[inanaco] 24/8/2023 09:21

a climate Bubble ..

"NOT in our part of France IT HAS NOT"

yet the other day he posted 50c plus

Alzheimer

he thinks its 1950

and Loz tries out to be a movie star in

"No Stock and two broken barrels" by Guy Ritchie

[marcusl2] 24/8/2023 08:50

“We believe that SCIB1 administration in combination with doublet therapy has the potential to offer greater efficacy than checkpoint inhibitors alone, without increasing toxicity," chief executive, professor Lindy Durrant, said.

[marcusl2] 24/8/2023 08:49

Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) has been approved by the European Commission (EC) as an adjuvant treatment in adults and adolescents with completely resected stage 2B or 2C melanoma.

The decision makes Opdivo, which is already approved in the EU for use in certain melanoma patients, the only PD-1 inhibitor authorised as an adjuvant treatment for patients within stages 2B, 2C and 3, as well as stage 4 resected melanoma.

The incidence of melanoma, a type of skin cancer that develops when pigment-producing cells located in the skin grow uncontrollably, has been rising steadily over the past few decades, with nearly 325,000 new cases diagnosed worldwide in 2020.


European Commission Approves the First and Only Immuno-Oncology Combination, Bristol-Myers Squibb’s Opdivo® (nivolumab) + Yervoy® (ipilimumab) Regimen, for Treatment of Advanced Melanoma
05/11/2016

[the real lozan] 24/8/2023 08:37

BBC Eurpoean weather forecast mis info -
The puppetboy CLAIMS "The HEAT has been 'relentless' across many parts of Europe through the summer, and yet again we're breaking records across Spain, it's been 'incredably HOT in France'...Blah blah
NOT in our part of France IT HAS NOT
Prior to the last few couple of weeks, for those of us who ACTUALLY live here (23 years and counting) it has been the 'POOREST' year we have had weatherwise.
Fruit growers and farmers agree = POOR
.
Why point this out LOZAN I hear folks ask.
Merely pointing out that LIEs,FALSE CLAIMS, long established here to mislead,..
Has become the norm in all forms of life
Tothe point where the 'weakest minds' MAKE-UP and 'defend' the LIEs and FALSE CLAIMS on a daily basis.
.
IF folks want to know the TRUTH - Look out of the window
OR
In the case of these forums - Look at the S P

[markingtime] 23/8/2023 15:45

Alzheimers.......

[markingtime] 23/8/2023 15:45

Alzheimers....

[marcusl2] 23/8/2023 14:13

All Scancell`s Glycans can be made into Car Ts. Amazing what Car T and Cell therapy has achieved.




Another Vulpes success story.
Oxford BioMedica is the sole manufacturer of the lentiviral vector that encodes the CD19-directed chimeric antigen receptor in Kymriah.

[the real lozan] 23/8/2023 14:00

First this year -
50 C in direct sun S facing terrace just now
54.1 C in direct sun W facing just now
Seen it all before....even hotter in years gone by
siesta time